Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385636 | 0.74 | IDO1 (0.41) | DRD3IDO1PLAU | |
| SCHEMBL12207680 | 0.74 | IDO1 (0.41) | DRD3IDO1PLAU | |
| SCHEMBL27410436 | 0.74 | IDO1 (0.46) | DRD3IDO1PLAU | |
| SCHEMBL14075393 | 0.73 | DRD3 (0.39) | DRD3IDO1 | |
| SCHEMBL31236844 | 0.69 | IDO1 (0.46) | DRD3IDO1PLAUACHE | |
| SCHEMBL315647 | 0.69 | BRD4 (0.54) | DRD3IDO1PLAUACHE | |
| SCHEMBL31236843 | 0.69 | IDO1 (0.46) | DRD3IDO1PLAUACHE | |
| SCHEMBL27704527 | 0.69 | IDO1 (0.37) | DRD3IDO1PLAU | |
| SCHEMBL7092682 | 0.68 | DRD3 (0.54) | DRD3IDO1HTR1A | |
| SCHEMBL31808827 | 0.68 | DRD3 (0.54) | DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675824-B1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | WURSTER SIEGFRIED (FI) | 2010-09-29 | — | — | EP | disclosed |
| US-7741362-B2 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SIEGFRIED WURSTER (FI) | 2010-06-22 | — | — | US | disclosed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2010-01-07 | — | — | US | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | OY JUVANTIA PHARMA LTD (FI) | 2007-06-07 | — | — | US | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
| EP-1692099-A1 | SOMATOSTATINE RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY | Oy Juvantia Pharma Ltd (FI) | 2006-08-23 | — | — | EP | disclosed |
| EP-1675824-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | Oy Juvantia Pharma Ltd (FI) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005056520-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY | OY JUVANTIA PHARMA LTD (FI) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033069-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| US-6468998-B1 | ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1125922-A1 | PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SSTR4, SSTR1, SSTR3 | DRD3 282/4885IDO1 1949/4885PLAU 3496/4885 |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | DRD3 214/4885IDO1 1915/4885PLAU 3353/4885 |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | SSTR4, SSTR1, SSTR3 | DRD3 282/4885IDO1 1949/4885PLAU 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.